ERBB2 and cancer: The present study was conducted on 449 invasive ductal carcinoma tumors; however, investigations conducted on a higher number of TNBC and HER-2-enriched cases, which belong to the most rare subtypes, may strengthen the evidence for the role of RBMS 3 in these types of cancers.